that encoded human cytochrome P450s 1A2, 2C9, 2C19, 2D6, or 3A4, or an empty plasmid vector (THLE-Null), was investigated. An automated screening platform, which included 1% dimethyl sulfoxide (DMSO) vehicle, 2.7% bovine serum in the culture medium, and assessed 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction, was used to evaluate the cytotoxicity of 103 drugs after 24 h. Twenty-two drugs caused cytotoxicity to THLE-Null cells, with EC 50 ≤ 200μM; 21 of these drugs (95%) have been reported to cause human liver injury. Eleven drugs exhibited lower EC 50 values in cells transfected with CYP3A4 (THLE-3A4 cells) than in THLENull cells; 10 of these drugs (91%) caused human liver injury. An additional 8 drugs, all of which caused human liver injury, exhibited potentiated THLE-3A4 cell toxicity when evaluated using a manual protocol that included 0.2% or 1% DMSO, but not bovine serum. Fourteen of the drugs that exhibited potentiated THLE-3A4 cell toxicity are known to be metabolized by P450s to reactive intermediates. These drugs included troglitazone, which was shown to undergo metabolic bioactivation and covalent binding to proteins in THLE-3A4 cells. A single drug (rimonabant) exhibited marked THLE cell toxicity but did not cause human liver injury; this drug had very low reported plasma exposure. These results indicate that evaluation of toxicity to THLE-Null and THLE-3A4 cell lines during drug discovery may aid selection of drugs with reduced propensity to cause drug-induced liver injury and that consideration of human exposure is required to enhance data interpretation.
Many hundreds of licensed drugs may cause drug-induced liver injury (DILI) in humans, and the most concerning clinical outcome is life-threatening liver failure. However, numerous drugs cause acute or chronic damage to the liver, which results in symptomatic liver injury but not liver failure, and some drugs cause asymptomatic abnormalities in serum clinical chemistry (most notably elevated concentrations of the enzyme alanine aminotransferase (ALT), which is released from damaged hepatocytes). DILI is an important cause of terminated development or failed registration of otherwise promising new therapies, of withdrawal of licensed drugs, and of cautionary and restrictive drug labeling (Kaplowitz and DeLeve, 2007) . For many drugs that cause DILI, the toxicity is not evident from conventional preclinical safety studies undertaken in experimental animals (Roth and Ganey, 2011) and occurs only infrequently in humans, in certain susceptible drug-treated patients; this is termed "idiosyncratic DILI" (Kaplowitz and DeLeve, 2007) .
The mechanisms that underlie DILI are complex and include both drug-related and patient-related processes. Drug-related processes determine whether or not individual drugs have the propensity to cause DILI in vivo, in preclinical test species or in humans. These arise via interaction of drugs and/or their metabolites with biochemical processes within liver cells that initiate and propagate tissue injury, or trigger protective responses. Notable examples include drug metabolism within hepatocytes to chemically reactive intermediates, impairment of mitochondrial function, inhibition of hepatic transporters that mediate transport of cytotoxic bile salts from hepatocytes into bile (especially the bile salt export pump [BSEP] ), initiation of oxidative stress, and activation of inflammatory processes and cell stress responses (Dawson et al., 2012; Dykens and Will, 2007; Greer et al., 2010; Thompson et al., 2011) . Patient-related processes play a major role in influencing whether or not drugs cause DILI in individual patients. These include genotype, underlying disease state, comedications that cause drug-drug interactions, adaptive immune responsiveness, gender, age, ethnicity, and other demographic factors (Pachkoria et al., 2007) . toxicological sciences 137(1), 189-211 2014 doi:10.1093/toxsci/kft223 Advance Access publication October 1, 2013 Many drug-related processes that initiate DILI can be evaluated using in vitro approaches. If used during drug discovery, when chemical choice is available, such methods could aid design and selection of drugs with reduced propensity to cause DILI (Greer et al., 2010; Thompson et al., 2011) . Models that express cytochrome P450 (P450) activity are likely to be especially useful, due to the role played by chemically reactive intermediates in DILI caused by numerous drugs and the importance of P450 enzymes in drug bioactivation (Park et al., 2011) . Because marked interspecies differences in P450-dependent drug metabolism may arise, systems that express human P450s could be of greatest value. Freshly isolated human hepatocytes express high P450 activities but are not ideally suited to highvolume screening due to their limited availability and high cost. Furthermore, marked interdonor variability in P450 expression may arise, and levels of expression of many P450s are downregulated when hepatocytes are cultured using conditions used in standard toxicity tests.
An alternative approach is to utilize human liver-derived cell line constructs that express human P450s. These can be generated in several ways. An especially promising approach comprises transfection of SV40 large T-antigen-immortalized human liver epithelial (THLE) cells (Pfeifer et al., 1993) with plasmid vectors that encode different human P450s (Bort et al., 1999; Macé et al., 1997) , which has yielded cell lines that exhibit stable P450 expression and excellent cell culture properties and have been used to explore the role played by P450s in drug metabolism (eg, Coulet et al., 1998; Molden et al., 2000) , metabolite-mediated genotoxicity (eg, Barceló et al., 1998; Pfeifer et al., 1993) , and cell toxicity (Dambach et al., 2005; Foster et al., 2013) . Recently, highly sensitive and specific discrimination between 27 drugs with marked or high propensity to cause idiosyncratic adverse reactions (primarily DILI) and 9 drugs with low propensity to cause such adverse reactions was observed when drug toxicity to THLE-3A4 cells or THLE-Null (which do not express P450s) was assessed alongside several other in vitro endpoints (Thompson et al., 2012) . The additional endpoints were mitochondrial toxicity to HepG2 cells, inhibition of the activities of BSEP and multidrug resistance protein type 2 (Mrp2), and dose-adjusted covalent binding (CVB) of radiolabeled drugs to human hepatocyte proteins.
To gain further insight into the value of THLE toxicity testing for assessment of human DILI propensity, we have investigated the toxicity of > 100 marketed drugs (83 of which caused DILI in humans) to THLE cell lines that selectively express CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or no P450s.
MATEriALS AND METHODS

Chemicals and Reagents
THLE cells expressing CYP1A2, 2C9, 2C19, 2D6, or 3A4, and THLENull cells, were obtained from Nestec Ltd (Lausanne, Switzerland) under an evaluation license. All experiments were conducted on cells between passages 8 and 40. Pooled cryopreserved human hepatocytes were obtained from Celsis/ In Vitro Technologies (Brussels, Belgium). The following reagents were obtained from Invitrogen Ltd (Paisley, United Kingdom): Basal Pasadena Foundation for Medical Research Medium #4 (PMFR4); GlutaMAX; fotal bovine serum (FBS; nonheat inactivated); Hanks balance salt solution without magnesium, calcium, and phenol red (HBSS−/−); Bis-Tris NuPAGE gels; PVDF mini and regular iBlot stack gels; Novex sharp prestain molecular weight markers; NuPAGE LDS sample buffer, sample reducing agent, and antioxidant. ECL plus, hyperfilm, and tracker tape were obtained from GE Healthcare (Little Chalfont, Buckinghamshire, United Kingdom). CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium [MTS] reagent) was obtained from Promega UK Ltd (Southampton, United Kingdom). Pierce BCA protein assay was obtained from Thermo Fisher Scientific Inc (Rockford, Illinois). BioCoat collagen I flasks and BioCoat collagen I 96well and 384well plates were obtained from BD Bioscience (Bedford, United Kingdom). All pharmaceutical drugs were provided by AstraZeneca Compound Management, AstraZeneca R&D, Macclesfield, United Kingdom, apart from [ 14 C]-troglitazone, which was obtained from Isotope Chemistry, AstraZeneca R&D and had a purity > 98% and a specific activity of 1.42 kBq/nmol. SDS was obtained from VWR (Lutterworth, Leicester, United Kingdom). Ultima Gold liquid scintillation cocktail was obtained from Perkin Elmer (Waltham, Massachusetts) . HPLC-grade acetonitrile, methanol, and ammonium acetate were obtained from Fisher-Scientific (Loughborough, United Kingdom). The antisera used in Western blotting experiments were obtained from Abcam (Cambridge, United Kingdom) (product code numbers: mouse anti-P450 1A2, 56073; rabbit anti-P450 3A4, 22704; rabbit anti-P450 2C, 78100) or from Millipore (rabbit anti-P450 2D6, AB10081; mouse antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH), CB1001). Horseradish peroxidase (HRP)-conjugated secondary antisera (HRP-anti-mouse IgG and HRP-anti-rabbit IgG) were provided by Cell Signaling Technology Inc via New England BioLabs (Ipswich, Massachusetts). All other reagents were obtained from Sigma-Aldrich Company Ltd (Poole, Dorset, United Kingdom).
Analysis of P450 Expression in THLE Cell Lines by Western Blotting
Collagen-coated 175-cm 3 flasks were seeded with THLE-1A2, 2C9, 2C19, 2D6, 3A4, or Null cells at a density of 1 million cells per flask in 30 ml PMFR (+) medium (basal PMFR4 medium plus 2mM GlutaMAX, 10 μg/ml recombinant human insulin, 5.5 μg/ml human transferrin, 5 ng/ml sodium selenite, 1nM hydrocortisone, 0.5 ng/ml epidermal growth factor, 35 μg/ml bovine pituitary extract, 0.33nM retinoic acid, 3% FBS, 150 μg/ml G418). The flasks were incubated in a humidified chamber at 37°C under 5% CO 2 for 3-4 days to enable the cells to adhere and grow to form confluent monolayers. The medium was removed, and the cells were washed with HBSS−/− and detached by addition of 1.5 ml 0.025% trypsin per flask. The detached cells were resuspended in PMFR (+) medium, sedimented by centrifugation at 300 × g for 3 min at room temperature, resuspended in radioimmunoprecipitation assay buffer at 7 million cells/ml (as determined using a hemocytometer), and stored frozen at -20°C prior to Western blotting. Twenty-five micrograms protein per lane (determined using the Pierce BCA protein assay, with bovine serum albumin as standard) was loaded onto Bis-Tris NuPAGE gels, which were run at 200 V for 1 h using NuPAGE equipment and reagents according to the NuPAGE Technical Guide. Proteins were transferred onto nitrocellulose (THLE-1A2, 3A4, and 2D6) or PVDF (THLE-2C9 and 2C19) membranes using an iBlot (Invitrogen). The membranes were blocked by incubation for 1 h in 5% nonfat milk/Tris-buffered saline (TBS) Tween 0.1% (TBST) and then incubated overnight at 4°C with primary antisera, which were diluted in 5% nonfat milk and TBS (anti-P450 1A2, 1:500; anti-P450 3A4, 1:2000; anti-P450 2D6, 1:2500; anti-P450 2C, 1:750). To verify that equivalent amounts of cell protein had been loaded in each lane, the anti-P450 antisera were combined with anti-GAPDH antiserum (1:20 000). Membranes were then washed with TBST, were incubated for 1 h at room temperature with appropriate HRP-conjugated secondary antisera diluted in 5% nonfat milk and TBST (anti-mouse IgG diluted 1:2000; anti-rabbit IgG diluted 1:2000), and after final washing were visualized by enhanced 190 Downloaded from https://academic.oup.com/toxsci/article-abstract/137/1/189/1645072 by guest on 21 April 2019 Drug ToxiciTy To THLE-cyP cELL LinEs chemiluminescence using ECL plus, as specified by the manufacturer. Pooled cryopreserved human hepatocytes were used as controls.
Assessment of THLE Cell Cytotoxicity
In the majority of experiments, nonautomated manual methods were used for compound dilutions, THLE cell culture, and assessment of cell toxicity. THLE-1A2, 2C9, 2C19, 2D6, 3A4, or Null cells were seeded into collagencoated 96-well tissue culture plates at a density of 15 000 cells per well in 200 μl PMFR (+) medium, and the plates were incubated for 24 h at 37°C in 5% CO 2 and 95% humidity to allow the cells to adhere and form monolayers. This cell seeding density was chosen because it resulted in a confluent cell monolayer, as assessed by light microscopy. The medium was then replaced with 200 μl of fresh PMFR (−) medium (basal PMFR (+) medium without insulin, transferrin, selenium, or FBS), which contained the test compound and dimethyl sulfoxide (DMSO) vehicle. All except one of the test compounds were solubilized initially in 100% DMSO, at a concentration of 30 or 150mM, and compound solubility was verified by visual inspection. The appropriate compound concentrations (between 0 and 500μM in a final concentration of DMSO of 0.2 or 1% (vol/vol)) were achieved by serial dilution of stock solutions into cell culture media, and cells were incubated with the test compounds for 24 or 48 h at 37°C in 5% CO 2 and 95% humidity. One of the test compounds (streptomycin) was insoluble in 100% DMSO and so was dissolved from an aqueous stock solution into culture medium that contained 0.2% DMSO. To assess toxicity, the media were then removed from each well and replaced with 120 μl of fresh PMFR (−) medium containing MTS reagent at a dilution of 1:6. Following further incubation at 37°C under 5% CO 2 for 1.5-2 h, absorbance at 492 nm was quantified using a Wallac EnVision spectrophotometer (Perkin Elmer). The CellTiter 96 AQueous Assay is composed of solutions of the tetrazolium compound MTS (inner salt) and the electron coupling reagent phenazine methosulfate. In metabolically active cells, MTS is reduced by mitochondrial dehydrogenase enzymes to a formazan product that is soluble in tissue culture medium and absorbs light at 490 nm. The absorbance at 490 nm is directly proportional to the number of living cells; therefore, this assay enables assessment of cell toxicity. It is a sensitive assay that requires fewer steps than other procedures that use tetrazolium compounds, such as 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT). Toxicity studies undertaken with rimonabant in THLE-3A4 cells have shown a close correlation between decreased cellular MTS signal and reduced ATP content (Foster et al., 2013) .
Toxicity of 103 drugs to THLE-Null and THLE-3A4 cell lines was investigated using a robotic platforms (Hamilton ML STAR [Hamilton Robotics]) for compound dilution, sterile dosing, and toxicity evaluation, as described elsewhere (Thompson et al., 2012) . The most significant alterations from the manual method were the following: adoption of 384-well plates rather than 96-well plates (which necessitated seeding of cells at 4000 cells/well to ensure subsequent cell confluency); use of robotics for all compound dilutions and liquid-handling steps; use of 1% DMSO vehicle to enhance compound solubility; and dilution of test compounds directly into PMFR4 cell growth medium (which contained insulin, transferrin, selenium, and FBS).
The percentage of viable cells relative to the vehicle-treated control wells was determined for each well, and EC 50 values, which represent the concentrations of the compounds that reduced MTS signal by 50%, were calculated with nonlinear regression for a sigmoidal dose response using the 4-parameter logistic equation in GraphPad Prism version 4.03 (GraphPad Software, San Diego, California) or Origin version 7.5 (OriginLab, Northampton, Massachusetts):
where y is the MTS signal; min, the bottom of the curve (set to 0%); max, the top of the curve of 100% (ie, the MTS signal of the vehicle control); x, the compound concentration; and EC 50 , half-maximal effective concentration characterizing the slope of the curve at its midpoint. All incubations within individual experiments were carried out in triplicate or duplicate. Because the quantity of formazan product measured by the absorbance at 490 nm in the MTS assay is directly proportional to the number of living cells in culture, a reduced MTS signal can be due to a decrease in cell proliferation and cell toxicity. Inspection of the dose-response curves, manual inspection of the cells by light microscopy, and evaluation of enzyme leakage using the lactate dehydrogenase assay are therefore advised when testing compounds that affect the rate of cell proliferation.
An EC 50 value of ≤ 200μM was used to identify drugs that caused toxicity in the assay, whereas an EC 50 value of ≤ 100μM was used to indicate drugs that exhibited marked toxicity. Potentiated toxicity to THLE-3A4 cells versus THLENull cells was defined as a ratio of THLE-Null EC 50 /THLE-3A4 EC 50 ≥ 1.4.
Metabolism of P450 Probe Substrates by THLE Cells
THLE cells were seeded into collagen-coated 6-well plates at 450 000 cells per well in 2.5 ml PMFR (+) medium and incubated for 24 h at 37°C in 5% CO 2 and 95% humidity. Six-well plates were used in order to increase the volume of culture media available for subsequent analysis. At the end of the incubation period, the medium was removed and each well was dosed with 2.5 ml PMFR (−) medium containing 20μM verapamil in 0.1% DMSO. After further incubation for 2 h at 37°C in 5% CO 2 and 95% humidity, 200-µl aliquots were removed and were mixed with equal volumes of cold acetonitrile and then stored at -80°C prior to analysis by HPLC. HPLC analyses were undertaken on an Accela HPLC system consisting of a binary solvent manager, column oven, sample manager, and diode array detector (Waters, Millford, Massachusetts), using a Synergi Fusion 100 × 2 mm (2.5 μm) column (Phenomenex, Macclesfield, United Kingdom). The mobile phases were 0.05% formic acid in water (A) and 0.05% formic acid in acetonitrile (B). The elution profile was as follows: linear gradient, 10%-90% B, 0.00-14.00 min; isocratic hold, 90% B, 14.01-18.00 min; reequilibration, 10% B, 18.01-20.00 min. The flow rate was 0.4 ml/min, and the column oven temperature was 30°C. The sample injection volume was 20 µl. Ultraviolet spectra were acquired from 200 to 350 nm.
To investigate the effect of DMSO concentration on P450 probe substrate clearance, THLE cells that had been seeded and incubated for 24 h postseeding in collagen-coated 96-well plates (as described for cell toxicity testing) were dosed with a probe substrate cocktail that contained 1μM phenacetin, dextromethorphan, and verapamil and 0.05 or 1% DMSO (vol/vol). The cells were incubated with the substrate cocktail with gentle mixing for 5 to 240 min at 37°C in 5% CO 2 and 95% humidity. Aliquots (140 μl) of the cell incubates were then mixed with equal volumes of ice-cold acetonitrile and were stored frozen at -80°C prior to analysis by HPLC.
Metabolism of P450 Probe Substrates by Human Hepatocytes
Loss of parent compound.
Cryopreserved human hepatocytes were quickly thawed in a 37°C water bath (1.5 min) and then resuspended by careful addition of 25 ml in Leibovitz buffer to 1 vial of cells. The cell suspension was equally divided into appropriate tubes, and centrifuged at 300 × g for 5 min, and the cells were resuspended in prewarmed (37°C) Leibovitz buffer to a density of 1 × 10 6 cells/ml. The cell suspension was transferred to 1-ml deep well plates, at 250 µl/well, and preincubated for 5 min at 37°C on a heated plate shaker. Probe substrate cocktail (2.5 μl) that contained 100μM verapamil, phenacetin, and dextromethorphan in 10% DMSO (final substrate concentration 1μM, in 0.1% DMSO) was added. After further incubation at 37°C on the heated plate shaker, 200-µl aliquots were removed after 0, 3, 6, 9, 12, and 15 min. These were added immediately to 200 µl ice-cold methanol, to stop the reaction, and centrifuged at 1800 × g for 15 min prior to analysis by HPLC. Protein determinations were undertaken using the Pierce BCA protein assay (Thermo Fisher Scientific Inc). The rate of loss of parent compound was calculated as the initial linear rate of clearance of the respective probe substrate over time (expressed as μl/min/mg protein).
Appearance of metabolite.
Cryopreserved human hepatocytes, THLE-2C9, THLE-3A4, or THLE-Null cells, were incubated as above in suspension culture at 1 × 10 6 cells/ml, with a probe substrate cocktail containing 2μM diclofenac and 3μM midazolam for 0, 5, 10, 15, 20, or 25 min, or with 10μM verapamil for 0, 3, 6, 12, or 15 min. At the indicated time points, aliquots (60 or 200 μl) were removed from the incubations and were mixed with ice-cold methanol (20 or 200 μl) to stop the reactions. The samples were centrifuged at 1800 × g for 15 min prior to analysis of the supernatants for the respective isoform-specific metabolites via mass spectrometry LCMS. Data for the 1-OH-midazolam and 4-OH diclofenac metabolites were acquired on an API4000 instrument (AB Sciex Instrument) with a HyPurity 50 × 2.1 mm, 5 μm column. The mobile phases were 0.1% formic acid, 5% acetonitrile in H 2 O (A), and 0.1% formic acid in 95% acetonitrile (B). The elution profile was as follows: linear gradient, 2%-3% B, 0.00-0.80 min; 3%-31% B, 0.80-3.10 min; 31%-98% B, 3.10-4.50 min; isocratic hold, 98% B, 4.50-5.00 min; reequilibration, 2% B, 5.10-6.00 min. The flow rate was 0.75 ml/min, and the column oven temperature was 40°C. The sample injection volume was 10 µl. The MS/MS ion transitions ranged from m/z 342.0 to 324 (positive ion mode) for 1′-hydroxymidazolam and from m/z 309.9 to 265.9 (negative ion mode) for 4′-hydroxydiclofenac. Data for the norverapamil metabolite were acquired on a Waters Platinum triple quadrapole with a Phenomenex max-rp 50 × 2.1 mm, 5 μm column. The mobile phases were 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). The elution profile was as follows: linear gradient, 5%-95% B, 0.00-3.00 min; isocratic hold, 95% B, 3.00-4.00 min; reequilibration, 5% B, 4.01-5.00 min. The flow rate was 0.6 ml/min, and the column oven temperature was 60°C. The sample injection volume was 20 µl. The MS/MS transition for detection of the norverapamil metabolite was m/z 441.3-165.4 (positive ion mode). The standard curves were linear up to 500nM. Protein determinations were undertaken using the Pierce BCA protein assay. The rate of specific metabolite formation was calculated as the initial linear rate of the formation of the respective metabolite over time (expressed as pmol/min/mg protein).
CVB to Proteins of [ 14 C]-Troglitazone in THLE Cells
THLE-3A4 or THLE-Null cells were seeded into collagen-coated 25-cm 2 tissue culture flasks at a density of 1.2 × 10 6 cells per flask in 5 ml PMFR (+) medium. Flasks of size 25 cm 2 were required to provide sufficient volumes of cells for subsequent detection of CVB. The flasks were incubated at 37°C for 24 h in 5% CO 2 and 95% humidity, and the medium was removed and was replaced with fresh PMFR (−) medium containing 10μM [
14 C]-troglitazone. The cells were incubated for a further 24 h at 37°C in 5% CO 2 and 95% humidity, washed with 2 × 5 ml HBSS−/−, scraped into 1 ml HBSS−/−, and then pelleted by centrifugation at 9000 × g for 1.5 min, at 4°C. To determine CVB, the supernatants were discarded and 300 μl ice-cold acetonitrile was added to the pellets. The acetonitrile extracts were harvested onto filter paper using a Brandel Cell Harvester ML-48TI (Brandel, Gaithersburg, Maryland) and washed with methanol (80% (vol/vol) in water). The filter papers were punched out individually and transferred to 20-ml glass scintillation vials, to which 1 ml of 5% SDS (wt/vol) in water was added. The vials were incubated overnight at 50°C. Aliquots (25 μl) of the resulting solutions were analyzed for protein content using the Pierce BCA protein assay, with bovine serum albumin as standard. Liquid scintillation cocktail (10 ml) was added to the remaining solutions, and total radioactivity was determined using a Beckman LS6500 MultiPurpose Liquid Scintillation Counter. Each sample was counted for 5 min or until the variance was ≤ 1%, using a protocol with quench correction. The values were corrected for background activity, and the levels of nonextractable radioactivity were expressed as picomole equivalents per milligram protein (pmol eq/mg protein), taking account of the protein concentration of each sample and the specific activity of the radiolabeled troglitazone. All incubations in individual experiments were performed in duplicate.
Metabolism of [ 14 C]-Troglitazone by THLE Cells
For metabolite quantification by LC-MS/MS, 10-μl aliquots of culture media obtained following incubation of THLE-3A4 and THLE-Null cells with 10μM [
14 C]-troglitazone for 24 h were injected using an autosampler (CTC Analytics HTC PAL, Presearch Ltd, Basingstoke, United Kingdom) onto a fused-core C18 reversed-phase HALO column (150 × 4.6 mm, 2.7 μm, Advanced Materials Technologies, Wilmington, Delaware) with a 2-mm (C18) precolumn guard filter (Hichrom Ltd, Reading, United Kingdom), all maintained at 40°C. Elution was over 14 min, using Agilent 1200SL series binary pumps (Agilent Technologies, Stockport, United Kingdom) at a flow rate of 0.5 ml/min. The mobile phases were 10mM ammonium acetate in H 2 O (unadjusted pH) (A) and 100% acetonitrile (B). The elution profile was as follows: 10% B, 0-2 min; linear gradient, 10%-95% B, 2.01-10 min; isocratic hold, 95% B, 10.01-12 min; reequilibration, 10% B, 12.01-14 min. Retention times for troglitazone and troglitazone sulfate (which were available as authentic standards) were typically 7.1 and 5.8 min, respectively, on this chromatographic system. Mass spectrometric analyses were conducted using a ThermoFinnigan LTQ linear ion trap instrument (Thermo Fisher Scientific, Bremen, Germany) fitted with an IonMax electrospray ionization source operating in negative ion mode under, with parameters optimized for troglitazone parent compound. The initial full MS scan ranged from m/z 400 to 600 in negative ion mode. This was followed by an MS 2 product ion scan of m/z 440.3 (troglitazone) and a further MS 2 product ion scan of m/z 520.3 (troglitazone sulfate). Collisionally induced fragmentation was conducted with an isolation width of 2 mass units (mu), a collision energy normalized to 35% for parent compound and an activation time of 30 ms. All of the HPLC eluent was introduced to the mass spectrometer to increase detection sensitivity but was diverted away from the mass spectrometer to waste from 0 to 3 min and 12 to 14 min, respectively.
Structural identification of troglitazone metabolites was assessed by qualitative and quantitative analyses of the chromatographic profiles obtained via [
14 C]-detection and consecutive fragmentation mass spectrometry (MS n ). Analysis of metabolites by HPLC-radioprofiling-MS n was undertaken using the same LC-MS configuration as above, except that the injection volume was 90 μl, the column temperature was set to 30°C, and elution was achieved over 60 min at a flow rate of 1 ml/min. The mobile phases were 10mM ammonium acetate in H 2 O containing 0.1% formic acid (A) and 0.1% (vol/vol) formic acid in acetonitrile (B). The elution profile was as follows: 5% B, 0-5 min; 5%-35% B, 5-8 min; 35%-60% B, 8-50 min; 60%-95% B, 50-52 min; isocratic hold, 95% B, 52-57 min; reequilibration, 5% B, 57-60 min. The postcolumn eluent was split 1:5 vol/vol between the mass spectrometer and radiodetector, respectively, using a QuickSplit binary fixed-flow splitter (Analytical Scientific Instruments, El Sobrante, California), to enable simultaneous MS and radiodetection. The HPLC eluent was diverted away from the mass spectrometer to waste from 0 to 1 min and 51 to 60 min, respectively. Radiochemical detection was performed on-line using a LabLogic β-Ram 3 detector (LabLogic Systems Ltd, Sheffield, United Kingdom) with a 500-µl liquid flow cell and Ultima Flo-M scintillation cocktail (Packard Instruments, Pangbourne, United Kingdom) running at 1.6 ml/min (ca. 2:1 vol/vol scintillant/eluent). Radiolabeled components were assumed to have the same specific activity as the parent drug. Mass spectrometric acquisition data scans were performed as a single segment throughout the analyses, with scan 1 being the full scan across a mass range of m/z 400-800, followed by multistage fragmentation studies (MS 2/3 ) conducted in collisional-induced dissociation (CID) mode in the linear ion trap. Scan 2 was, therefore, typically conducted in data-dependent mode, with the most intense of the prelisted expected masses isolated using a 2.0-mu window, and collision energies were normalized to 25% (CID) for troglitazone (m/z 440). The subsequent scan 3 was typically a data-dependent scan derived from the most intense ion afforded in scan 2, again isolated with a 2.0-mu window and collision energies normalized to 35%.
Other multistage fragmentation (MS n ) experiments involved targeted (defined) scans of selected precursor ions rather than data-dependent listed ions, irrespective of the previous full scan data sets. These targeted MS n data sets used the same scan 2/3 settings described above.
The radiometric data were collected and analyzed using LAURA version 3.4.1.10e (Lablogic Systems Ltd, Sheffield, United Kingdom), whereas MS n data were collected using Xcalibur version 2.0.7 (Thermo Fisher Scientific, Waltham, Massachusetts). Components were identified as being derived from Statistical analysis. Statistical analyses were performed using GraphPad Prism paired t test or ANOVA.
rESuLTS
DILI Categorization of Tested Drugs
Currently, there is no agreed consensus approach for classification of DILI in humans, which is suitable for use when evaluating potential in vitro assays that might aid selection of drugs with low propensity to cause clinically concerning DILI during drug discovery. We, therefore, used information on DILI in humans caused by the 104 tested drugs, which was extracted from the scientific literature and from U.S. FDAapproved product labels, to assign each drug to 1 of 5 DILI concern categories. These are summarized in Table 1 , as are the pharmacology classes of the drugs and their patterns of human liver injury (hepatocellular, cholestatic, or mixed). Category 1 drugs (n = 24) caused cases of fatal liver failure, which had resulted in either withdrawal or FDA Black Box Warnings and were termed "Severe DILI." Category 2 drugs (n = 27) caused cases of liver failure that resulted in cautionary labeling and restricted drug usage, but not Black Box Warnings or drug withdrawal, and were categorized as "High concern." Category 3 drugs (n = 32) caused isolated and extremely infrequent cases of DILI, which also resulted in cautionary labeling and were termed "DILI reports." Category 4 drugs (n = 8) caused asymptomatic elevations in levels of serum ALT, but not liver injury, and were termed "ALT elevations." Category 5 drugs (n = 13) have not been reported to result in any evidence of liver signals in humans and were categorized as "No liver signals."
Recently, 68 of the 103 drugs have been assigned to 1 of 3 DILI concern classes (High, Low, or No Concern) by other investigators, who considered the clinical severity of DILI reported in the clinic and labeling approved by U.S. FDA (Chen et al., 2011) . This information has been summarized in Table 1 as "LTKB class." All of the 24 category 1 drugs had been assigned to LTKB classification "Most DILI concern," as had 12 category 2 drugs. Six category 2 drugs had been described as LTKB "Less DILI concern." These were as follows: carmustine, indomethacin, ranitidine, which have been reported to cause fatal hepatic injury; clozapine, which has been reported to cause fulminant hepatic failure; azathioprine, which has been associated with life-threatening hepatic veno-occlusive disease; and flurbiprofen, which may cause progressive liver injury that results in fatality. Three category 3 drugs (acitretin, methimazole, and zimelidine) have been classified as LTKB "Most DILI concern," whereas 13 category 3 drugs were classified as LTKB "Less DILI concern." Two category 4 drugs (buspirone and dexamethasone) were assigned to LTKB class "Less DILI concern." Three category 5 drugs (betaine, isoproterenol, and streptomycin) were assigned to LTKB class "No DILI concern." Data on the prescribed doses of the drugs, their extents of plasma protein binding, their maximum reported plasma concentration, and their estimated maximum unbound plasma concentrations (C max,u ) were also extracted from the scientific literature and are summarized in Supplementary Table 1 . Drugs in all 5 DILI categories exhibited similarly broad ranges of C max,u values (see Supplementary Figure 1 ).
P450 Enzyme Expression and Activity in THLE Cell Lines
Expression of P450 proteins in the THLE cell lines was investigated by Western blotting analysis, using specific antisera. This revealed no detectable expression of P450 enzymes 1A2, 2C, 2D6, or 3A4 in the THLE Null cell line (Fig. 1) . Selective expression of the P450 enzymes 1A2, 2D6, and 3A4 was observed in the corresponding cell lines. The anti-P450 2C antiserum, which was unable to discriminate between P450s 2C19 and 2C9, recognized proteins present in both the THLE-2C19 and THLE-2C9 cell lines but not in the other cell lines. Apparent levels of expression of CYP3A4 were similar in THLE-3A4 cell lysates and pooled human hepatocyte lysates, whereas higher apparent levels of expression of CYP1A2, CYP2Cs, and CYP2D6 were observed in the corresponding THLE cell lysates than in human hepatocyte lysates (Fig. 1) .
P450 enzyme activities of the THLE cell lines were explored using specific probe substrates ( Table 2) . None of the probe substrates were metabolized in the THLE-Null cell line. Extensive and specific clearance of phenacetin (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), and verapamil (CYP3A4 substrate) was observed in the appropriate transfected cell lines (THLE-1A2, THLE-2D6, and THLE-3A4, respectively). An illustrative LC profile for verapamil in the THLE-3A4 and THLE-2D6 cells is shown in Supplementary Figure 2 . Quantification of the rates of disappearance of the parent compounds was used to estimate the corresponding enzyme activities. It was found that the rates of clearance of phenacetin in THLE-1A2 cells and of dextromethorphan in THLE-2D6 cells were similar to the rates of clearance of these substrates in cryopreserved human hepatocytes. However, the rate of clearance of verapamil in THLE-3A4 cells was about one-third of its rate of clearance in human hepatocytes ( Table 2 ). The impact of DMSO concentration on substrate clearance in THLE cells was investigated because DMSO was the vehicle used to facilitate drug solubility in cell toxicity studies. The rate of dextromethorphan clearance in THLE-2D6 cells was similar when determined at 0.05% and 1% DMSO, whereas the rates of phenacetin clearance in THLE-1A2 cells and of verapamil clearance in THLE-3A4 cells were reduced by about 40% at the higher DMSO concentration ( Table 2) .
The extents of clearance of the CYP2C9 substrate diclofenac and the CYP3A4 substrate midazolam were insufficient to enable robust quantification of the corresponding enzyme activities from the rates of loss of the parent compounds. Therefore, for these substrates, metabolite formation was quantified by LC-MS, using appropriate authentic reference standards. Verapamil metabolite formation (catalyzed by CYP3A4) 
Less DILI concern Drug ToxiciTy To THLE-cyP cELL LinEs was also quantified using this approach in THLE-3A4 cells. Very similar rates of diclofenac metabolism were observed in THLE-2C9 cells and human hepatocytes. In contrast, the observed rate of midazolam and verapamil metabolite formation was approximately 30-and 17-fold lower, respectively, in THLE-3A4 cells than in human hepatocytes (Table 2) .
Drug Toxicity to THLE Cells
Initial THLE cell toxicity studies involved the use of manual methods for compound dilution and liquid handling and were undertaken using cells cultured in 96-well plates in the presence of 0.2% DMSO. Typical dose-response curves for 4 drugs are shown in Figures 2 and 3 . Marked toxicity (EC 50 ≤ 100μM) was evident when the cells were exposed to chlorpromazine, troglitazone, and rosiglitazone for 24 h, which was more potent in THLE-3A4 cells than in THLE-Null cells or in THLE cells, which expressed other CYPs. However, no toxicity was observed when the THLE cells were exposed to streptomycin. The EC 50 values obtained with these drugs and an additional 4 drugs are summarized in Table 3 . Clozapine and diclofenac exhibited both THLE-Null cell toxicity and potentiated toxicity to THLE-3A4 cells (THLE-Null/THLE-3A4 EC 50 ratio ≥ 1.4), whereas ibuprofen and practolol did not. Both troglitazone and rosiglitazone exhibited poor solubility in cell culture medium that contained 0.2% DMSO, whereas warming and repeated pipetting of the culture media were required in the case of clozapine to achieve the higher drug concentrations required to generate full dose-response curves for toxicity.
The solubility of rosiglitazone and clozapine in culture medium was improved markedly when the DMSO concentration was increased to 1%. Cell toxicity EC 50 values obtained in the presence of 1% DMSO for the 8 drugs that had been evaluated at 0.2% DMSO are summarized in Table 3 . The 3 drugs that did not cause cell toxicity in 0.2% DMSO (ibuprofen, practolol, and streptomycin) were also nontoxic in 1% DMSO. Three drugs (chlorpromazine, clozapine, and rosiglitazone) 
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exhibited THLE-Null cell toxicity and potentiated toxicity to THLE-3A4 cells at both DMSO concentrations, although the EC 50 values at 1% DMSO were up to 1.5-fold higher than those observed at 0.2% DMSO. For both troglitazone and diclofenac, potentiated toxicity to THLE-3A4 cells was observed at 0.2% DMSO but not at 1% DMSO. In view of the improved compound solubility that could be achieved at 1% DMSO, this vehicle concentration was used in subsequent cell toxicity studies. Data obtained for an additional 26 drugs using the manual protocol are shown in Table 3 . Overall, 23 of the drugs evaluated under these conditions caused DILI, and 13 drugs (57%) exhibited toxicity to one or more THLE cell lines. Twelve drugs that were toxic to THLE cells (DILI category 1, 2, or 3) exhibited potencies of toxicity similar to that of THLE-Null, THLE-1A2, THLE-2C9, and THLE 2D6 cell lines, whereas 8 drugs exhibited more potent toxicity to THLE-3A4 cells than to THLE-Null cells or the other cell lines. In addition, 1 drug that exhibited marked toxicity to THLE-Null cells (disulfiram) caused less potent toxicity to THLE-3A4 cells (see Table 3 ). None of the 11 drugs that did not cause DILI (DILI category 4 or 5) were toxic to THLE cells.
Investigation of the published scientific literature provided evidence that 10 of the 11 drugs that exhibited potentiated toxicity to THLE-3A4 cells when tested using the manual protocol (amiodarone, ketoconazole, troglitazone, amodiaquine, clozapine, diclofenac, rosiglitazone, terbinafine, chlorpromazine, and propranolol) are metabolized to reactive intermediates (see Table 4 ). No data could be found in the scientific literature, either positive or negative, on whether the remaining drug that exhibited potentiated THLE-3A4 cell toxicity (bosentan) might be metabolized to reactive intermediates.
Metabolic Bioactivation of [
C]-Troglitazone in THLE-3A4 Cells
Radiochemical LC profiling of supernatants obtained following incubation of radiolabeled troglitazone with THLE-Null and THLE-3A4 cells revealed that numerous metabolites were produced in both cell lines (Fig. 4) . Their chemical structures were investigated by LC-MS n , which provided evidence of 2 sulfated conjugates (M3 and M4), a hydroxylated metabolite (M5), and a polar radiopeak that eluted early (M1) and whose chemical structure could not be assigned due to its close proximity to the solvent front (Table 5 ). In addition, a metabolite (M2) was detected in media from THLE-3A4 cells, but not in media from THLE-Null cells, which exhibited a molecular mass at m/z 745 that is consistent with direct conjugation of glutathione (a mass increment of 305 mu) with troglitazone (m/z 440). This metabolite afforded fragments corresponding to the loss of pyroglutamic acid (m/z 618, m/z 747-129), as well as characteristic glutathione molecular (m/z 306; glutathione) and fragment ions (m/z 272; glutathione-SH 2 and m/z 254; glutathione-SH 2 -H 2 O), providing further confirmation that it was a glutathione conjugate. The magnitude of irreversible binding of radiolabel derived from troglitazone to THLE-3A4 cell proteins was markedly greater than its magnitude of binding to THLE-Null cell proteins (Table 6 ).
Screening of 103 Drugs for Toxicity to THLE-Null and THLE-3A4 Cells
In order to facilitate evaluation of THLE cell toxicity of a larger number of drugs, the manual protocol was modified to 203 enable rapid and high-volume data generation. The most significant alterations were adoption of 384-well plates rather than 96-well plates, use of robotics for all compound dilutions and liquid handling steps, evaluation only of THLE-3A4 and THLENull cells, and dilution of the test compounds directly into PMFR (+) growth medium that contained 2.7% bovine serum.
Compound dilution directly into the cell growth medium simplified the liquid handling protocol, and 1% DMSO was used to facilitate compound solubility. Toxicity data obtained with 30 drugs using the automated protocol at 24 or 48 h after compound administration are shown in Supplementary Figure 4 .
No clear differences were evident between data obtained at these 2 time intervals; therefore, cells were exposed to test compounds for 24 h in subsequent experiments. Typical cell toxicity dose-response curves obtained with 3 drugs are shown in Figure 5 . Toxicity data obtained with the 103 tested drugs in THLE-Null and THLE-3A4 cells are summarized in Table 7 and in Figure 6 . Twenty-seven drugs exhibited evidence of toxicity when evaluated using the automated protocol. For several drugs, the effect was minimal and was only apparent at the highest tested drug concentration of 300μM. Visual inspection of Table 4 is also shown. Abbreviations: DMSO, dimethyl sulfoxide; GSH, glutathione; TGZ, troglitazone; THLE, T-antigen-immortalized human liver epithelial. 440 412, 397, 369, 363, 276, 233, 222, 221, 199, 179, 178, 162, 145, 137, 119 Table 7 ) and 4 drugs exhibited greater toxicity to THLENull cells than to THLE-3A4 cells (Table 7) .
Seven of the 11 drugs that exhibited potentiated THLE-3A4 cell toxicity (THLE-Null/THLE-3A4 EC 50 ratio ≥ 1.4) when tested using the automated protocol have been reported to be metabolized to reactive intermediates (see Table 4 ). Three of these drugs (amiodarone, clozapine, and chlorpromazine) exhibited potentiated toxicity to THLE-3A4 cells when tested using both protocols. However, 8 drugs (bosentan, ketoconazole, troglitazone, amodiaquine diclofenac, rosiglitazone, terbinafine, and propranolol) exhibited potentiated THLE-3A4 cell toxicity when evaluated using the manual protocol, but not when tested using the automated protocol.
Twenty-one of the 22 drugs that exhibited THLE-Null cell toxicity (95%) and 10 of the 11 drugs that exhibited potentiated toxicity to THLE-3A4 cells (91%) have been reported to cause DILI in humans. Therefore, the assay exhibited high specificity/positive predictive value (PPV) for DILI. However, many drugs reported to cause DILI did not exhibit THLE-cell toxicity; therefore, its DILI sensitivity/negative predictive value (NPV) was modest (Table 8 ). The drugs that exhibited THLE cell toxicity were distributed across all 3 DILI severity categories ( Fig. 8 and Tables 7 and 8), although the frequencies of THLE-Null cell toxicity and of potentiated THLE-3A4 cell toxicity were higher among drugs categorized as Severe DILI than among drugs categorized as High DILI concern or DILI reports (Table 8 ). There was no apparent association between the THLE cell toxicity data and whether the tested drugs were reported to cause hepatocellular, cholestatic, or mixed patterns of liver injury (Fig. 8) .
One drug that exhibited marked THLE-Null cell toxicity and also markedly potentiated toxicity to THLE-3A4 cells did not cause DILI; this was rimonabant. The maximum unbound plasma concentrations of this drug, and of the other 103 drugs, were calculated from C max and plasma protein binding values that were obtained from the published scientific literature (see Supplementary Table 1 ). This value was much lower for rimonabant than for any of the other tested drugs (Fig. 9) . Furthermore, the total uncorrected plasma C max of rimonabant was much lower than the corresponding values for the other tested drugs (Supplementary Table 1 ).
DiSCuSSiON
The P450 expression and activities we observed in THLE cell lines transfected with CYP1A2, CYP2C9, CYP 2C19, (Pfeifer et al., 1993; Soltanpour et al., 2012) . Initial toxicity studies revealed limited solubility of several drugs in the cell culture medium; therefore, concentrated stock solutions were prepared in 100% DMSO and diluted into culture medium. Although numerous drugs could be dissolved readily in medium that contained 0.2% DMSO, some compounds exhibited relatively poor solubility in 0.2% DMSO, which was not evident at 1% DMSO. Consequently, the higher DMSO concentration was used to investigate THLE cell toxicity of > 100 drugs, which utilized a fully automated assay protocol. When evaluated using this protocol, 22 of 103 drugs exhibited toxicity to THLE-Null cells which can be attributed to P450 independent mechanisms. A possible contributory factor is mitochondrial injury, which has been observed for the majority of the drugs that exhibited such toxicity (Dykens and Will, 2007) , although other mechanisms cannot be excluded. Four drugs (cinchophen, lumiracoxib, tolcapone, and glibenclamide) caused less potent toxicity to THLE-3A4 cells than to THLE-Null cells, which is suggestive of detoxification by CYP3A4, whereas 11 drugs exhibited more potent THLE-3A4 cell toxicity. These included rimonabant, which is metabolized by CYP3A4 to a chemically reactive and cytotoxic iminium ion intermediate (Foster et al., 2013) , whereas 6 of the other 10 drugs (amiodarone, benzbromarone, nefazodone, clozapine, glafenine, and chlorpromazine) are also metabolized to reactive intermediates. No data could be identified on whether or not the remaining drugs (celecoxib, acitretin, amlodipine, and fusidic acid) are metabolized to reactive species. Eight drugs (bosentan, ketoconazole, troglitazone, amodiaquine, diclofenac, rosiglitazone, terbinafine, and propranolol) exhibited potentiated THLE-3A4 cell toxicity when tested using the manual protocol, which was not evident using the automated protocol. Three of these drugs (troglitazone, rosiglitazone, and diclofenac), all of which are metabolized to reactive intermediates, exhibited potentiated THLE-3A4 toxicity when tested using the manual protocol at 0.2% DMSO but not at 1% DMSO. Concentration-dependent suppression of several P450 enzymes activities by DMSO has been observed (Easterbrook et al., 2001;  Table 1 ), which implies a role for P450-dependent metabolism in the toxicity as do the investigative studies undertaken with troglitazone. These identified a glutathione 4 of which have been reported to be metabolized by P450s to reactive intermediates) exhibited potentiated THLE-3A4 cell toxicity in the presence of 1% DMSO when evaluated using the manual protocol, but not using the automated protocol. Because these drugs exhibit high plasma protein binding (> 1. Severe (n = 24) n = 7 (29%) PPV 95% n = 3 (13%) PPV 91% 2. High concern (n = 27) n = 6 (22%) n = 3 (11%) 3. DILI reports (n = 32) n = 5 (16%) n = 4 (13%) 4. ALT elevations (n = 8) n = 0 (0%) NPV 23% n = 0 (0%) NPV 21% 5. No liver signals (n = 12) n = 1 (8%) n = 1 (8%) NPV, negative predictive value; PPV, positive predictive value.
a
The maximum soluble concentration of rimonabant was 30μM. 94%; see Supplementary Table 1 ) and 2.7% bovine serum was present when cells were incubated with test compounds in the automated protocol, but not in the manual protocol, binding to bovine serum proteins might help explain this finding. Other differences between the protocols that could be relevant include the different cell seeding densities and ratios of cells to media present in wells of 384well plates versus 96well plates.
Four drugs that exhibited potentiated THLE-3A4 cell toxicity (amiodarone, clozapine, nefazodone, and troglitazone) have been reported to exhibit potentiated toxicity to other human liver-derived and CYP3A4 transfected cell lines due to CYP3A4-dependent metabolism Vignati et al., 2005; Zahno et al., 2011) . In addition, HepG2 cells transfected with multiple P450 enzymes (CYPA2, CYP2D6, CYP2C9, CYP2C19, and CYP3A4) exhibited greater susceptibility to toxicity caused by chlorpromazine and diclofenac than nontransfected HepG2 cells (Tolosa et al., 2013) . Relatively modest potentiation of drug toxicity to cells expressing P450s was observed in these studies, which also is in line with our results.
The estimated EC 50 values for THLE cell toxicity ranged from low μM (eg, amiodarone, tolcapone) to > 100μM (eg, clozapine, rosiglitazone). These concentrations are far higher than the estimated C max,u concentrations of the majority of the drugs in human peripheral blood. However, our estimated EC 50 values assumed no binding of drugs to proteins or lipids; many of the drugs exhibit high plasma protein binding, and the automated toxicity protocol included 2.7% FBS. Therefore, the true in vitro EC 50 values could be much lower than the estimated values. It is also possible that our data have underestimated potencies of toxicity to liver cells in vivo, where DMSO is absent, due to suppression of P450 enzyme activity by DMSO (Easterbrook et al., 2001) and because DMSO has antioxidant properties (Sanmartín-Suárez et al., 2011) . Furthermore, many drugs and their metabolites accumulate within hepatocytes in vivo at concentrations that are much higher than those in peripheral blood due to transport across the sinusoidal plasma membrane domain, which is mediated by solute carriers (Grime et al., 2008 ) not expressed in cultured THLE cells (Soltanpour et al., 2012) and first pass metabolism. Further work will be required to clarify the relationship between drug concentrations that cause THLE cell toxicity in vitro and within livers of patients in vivo.
The marked THLE-3A4 cell toxicity of rimonabant, which was withdrawn due to severe behavioral adverse effects but did not cause DILI, highlights that care needs to be taken when extrapolating from in vitro toxicity signals observed with individual compounds to DILI hazard and risk in vivo. The estimated plasma exposure of rimonabant was much lower than that of the other tested drugs due to its low PO daily dose of 20 mg and its very high extent of plasma protein binding. This indicates that consideration of anticipated (or ideally measured) human exposure is required to aid interpretation of THLE cell toxicity data.
Our toxicity studies with 34 drugs did not reveal potentiated THLE-1A2, THLE-2C9, or THLE-2D6 cell toxicity. However, potentiated toxicity was observed when Huh7 cells transfected with CYP1A2 were exposed to furafylline, evoxine, and thimerosal (Chu et al., 2011) , whereas benzbromarone, losartan, and tienilic acid caused toxicity to HepG2 cells transfected with CYP2C9 when the Nrf2-dependent antioxidant response was impaired by small inhibitory RNA knockdown . Therefore, evaluation of additional drugs in the full range of THLE-CYP cell lines may enable detection of drug toxicity mediated by P450s other than CYP3A4. Undertaking such studies using matched numbers of hepatotoxic and nonhepatotoxic drugs should enhance understanding of the PPV and NPV of the data for human DILI.
Other investigators have observed a good correlation between toxicity to THLE-Null cells, and toxicity caused by test compounds to various target organ systems in preclinical animal safety studies (Benbow et al., 2010) . The relationship between potentiated toxicity to THLE cells that express P450s and organ toxicity in animals was not explored in the present studies, but merits investigation in the future. It will also be important to explore whether THLE cell toxicity data correlate with clinically important human adverse reactions to organs other than the liver (eg, kidney or heart).
A higher frequency of THLE cell toxicity was observed among drugs categorized as Severe DILI than among drugs categorized as High DILI concern or DILI reports. However, the THLE cell toxicity data did not discriminate reliably between drugs in the 3 DILI categories. They also did not differentiate between drugs that caused hepatocellular, cholestatic, or mixed DILI patterns and provided only modest DILI sensitivity (ie, many drugs that caused DILI did not exhibit THLE cell toxicity). THLE cells evaluate only some of the numerous adverse drug-related processes that may initiate DILI. Relevant additional contributory mechanisms include mitochondrial injury, Fig. 9 . Comparison between C max,u , potency of THLE-3A4 cell toxicity and DILI severity category. Each data point represents an individual drug (1. • severe; 2. ○ high concern; 3. ■ DILI reports; 4. □ ALT elevations; 5. △ no liver signals). Abbreviations: ALT, alanine aminotransferase; DILI, drug-induced liver injury; THLE, T-antigen-immortalized human liver epithelial.
inhibition of the biliary transporters BSEP and Mrp2, and formation of reactive metabolites (Dawson et al., 2012; Greer et al., 2010; Thompson et al., 2011) . The value of multiparametric evaluation of DILI propensity has also been highlighted recently by other investigators (Sakatis et al., 2012) . It has been proposed that THLE-Null and THLE-3A4 cell toxicity should be evaluated alongside methods that assess these other mechanisms, when selecting drugs with reduced propensity to cause human adverse reactions (Thompson et al., 2012) . The present results are consistent with this approach, which currently is being used within AstraZeneca to support compound selection during drug discovery.
Although the automated protocol enabled convenient screening of large numbers of compounds, it provided less sensitive detection of THLE-3A4 cell toxicity (hence DILI propensity) than the labor-intensive manual protocol, which is poorly suited to high-volume screening. Optimal value from THLE-cell toxicity testing during drug discovery might, therefore, be obtained by utilizing the automated assay as a high-volume initial "filter," and then using the manual protocol to generate more robust data at key decision points (eg, when selecting lead series for optimization, or prioritizing compounds for in vivo safety testing). Moreover, investigative studies of metabolism and CVB, as exemplified by those undertaken with troglitazone, provide insight into mechanisms of potentiated toxicity to THLE cells expressing P450s, which aids risk assessment and/or design and selection of safer compounds.
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